Join
Live feed
·
PRReleasevia Quantisnow
AbbVie Inc. logo

AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease

ByQuantisnow·Wall Street's wire, on your screen.
ABBV· AbbVie Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABBV (AbbVie Inc.) and more on Quantisnow.